Biosimilar agents in oncology/haematology: From approval to practice

European Journal of Haematology

Volumn 86, Issue 4, 2011, Pages 277-288

  Niederwieser, Dietger ^a   Schmitz, Stephan ^b  

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^b Onkologische Schwerpunktpraxis   (Germany)

Author keywords

Biologics; Biosimilars; Extrapolation; Granulocyte colony stimulating factor; International non proprietary names; Substitution; Traceability

Indexed keywords

ALBINTERFERON ALPHA2B; BETA1A INTERFERON; BIOLOGICAL PRODUCT; CD20 ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; GAMMA1B INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH HORMONE; INSULIN; INTERLEUKIN 2; MONOMER; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT HUMAN INSULIN; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; VASCULOTROPIN ANTIBODY;

AWARENESS; BREAST CANCER; CLINICAL PRACTICE; CLINICAL PROTOCOL; DRUG APPROVAL; EUROPE; FOOD AND DRUG ADMINISTRATION; HEMATOLOGY; HUMAN; IMMUNOGENICITY; INFORMATION; NEUTROPENIA; ONCOLOGY; PHYSICIAN; PRIORITY JOURNAL; PROFESSIONAL PRACTICE; PROTEIN SECONDARY STRUCTURE; PROTEIN TERTIARY STRUCTURE; REVIEW; SAFETY;

ANTINEOPLASTIC AGENTS; BIOLOGICAL PRODUCTS; DRUG APPROVAL; DRUG TOXICITY; EUROPEAN UNION; FILGRASTIM; HEMATINICS; HEMATOLOGIC AGENTS; HUMANS;

EID: 79952749322     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2010.01566.x     Document Type: Review

References (93)

1. Schellekens H. Follow-on biologics: challenges of the 'next generation'. Nephrol Dial Transplant 2005;20:31-6.
2. Kuhlmann M, Covic A. The protein science of biosimilars. Nephrol Dial Transplant 2006;21:4-8.
3. Mellstedt H, Niederwieser D, Ludwig H. The challenge of biosimilars. Ann Oncol 2008;19:411-9.
4. Lanthier M, Behrman R, Nardinelli C. Economic issues with follow-on protein products. Nat Rev Drug Discov 2008;7:733-7.
5. European Medicines Agency. Guideline on similar biological medicinal products (CHMP/437/04). Available from.
6. Declerck P. Biotherapeutics in the era of biosimilars: what really matters is patient safety. Drug Saf 2007;30:1087-92.
7. Schellekens H. The first biosimilar epoetin: but how similar is it? Clin J Am Soc Nephrol 2008;3:174-8.
8. European Medicines Agency. Questions and Answers on biosimilar medicines (similar biological medicinal products) (EMEA/74562/2006). Available from.
9. Declerck P. Biologicals in the era of biosimilars: implications for naming and prescribing. Eur J Hosp Pharmacy Practice 2007;13:51-3.
10. Mellstedt H, Crommelin DJA, Aravind SK, et al. Interpretation of the new EMEA guidelines in similar biological medicinal products. European Journal of Hospital Pharmacy Practice 2007;13:68-74.
11. European Medicines Agency. Procedures for marketing authorisation, Notice to Applicants, ENTR/F2/BL D(2002) Rev 3.(Chapt 1) Available from.
12. European Medicines Agency. Human Medicines - EMEA Procedural Advice for Users of the Centralised Procedure for Generic/Hybrid Applications (EMEA/CHMP/225411/2006). Available from.
13. European Medicines Agency. Topic 5QC - Quality of Biotechnological Products: Stability Testing of Biotechnological/Biological Products (CPMP/ICH/138/95 ICH - Adopted December 1995). Available from.
14. European Medicines Agency. ICH Topic S6, preclinical safety evaluation of biotechnology-derived pharmaceuticals (CPMP/ICH/302/95 - Adopted March 1998). Available from.
15. European Medicines Agency. CPMP/QWP/328/99 - development pharmaceutics for biotechnological and biological products - Annex to Note for Guidance on Development Pharmaceutics (CPMP/QWP/155/96). Available from.
16. European Medicines Agency. ICH Topic Q6B, Step 4 Note For Guidance on Specifications: test Procedures and Acceptance Criteria for Biotechnological/Biological Products (CPMP/ICH/365/96 - Adopted March 1999). Available from.
17. European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (EMEA/CHMP/BWP/49348/2005). Available from.
18. European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues (EMEA/CHMP/BMWP/42832/2005). Available from.
19. European Medicines Agency. Annex to guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues - guidance on similar medicinal products containing - somatropin (EMEA/CHMP/BMWP/94528/2005). Available from.
20. European Medicines Agency. Annex to guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues - Guidance on similar medicinal products containing recombinant human soluble insulin (EMEA/CHMP/BMWP/32775/2005). Available from.
21. European Medicines Agency. Guideline on similar medicinal products containing recombinant interferon alpha (EMEA/CHMP/BMWP/102046/2006). Available from.
22. European Medicines Agency. Annex to guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues - Guidance on similar medicinal products containing recombinant erythropoietins (EMEA/CHMP/BMWP/94526/2005). Available from.
23. European Medicines Agency. Annex to guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues - Guidance on similar medicinal products containing recombinant granulocyte-colony stimulating factor (EMEA/CHMP/BMWP/31329/2005). Available from.
24. European Medicines Agency. Guideline on similar biological medicinal products containing low-molecular-weight-heparins (EMEA/CHMP/BMWP/118264/2007). Available from.
25. European Medicines Agency. European Medicines Agency - Overview Website of Current Legislation on Biosimilars. Available from.
26. U.S.Government. Public Law No. 111-148 (formerly H.R. 3590), the Patient Protection and Affordable Care Act, TITLE VII-IMPROVING ACCESS TO INNOVATIVE MEDICAL THERAPIES, Subtitle A-Biologics Price Competition and Innovation. Available from.
27. WHO. Expert Committee on Biological Standardization, Geneva, 19 to 23 October 2009. Guidelines on Evaluation of Similar Biotherapeutic Products (SBPs). Available from.
28. WHO. Guidance on INN. Available from.
29. WHO. WHO Informal Consultation on International Nonproprietary Names (INN) Policy for Biosimilar Products. INN Working Document 07.211. Geneva, 4-5 September 2006. Available from.
30. Australian Government Department of Health and Ageing and Therapeutic Goods Administration (TGA). European Union guidelines adopted in Australia - Similar Biological Medicinal Products. Available from.
31. Bohlega S, Al-Shammri S, Al Sharoqi I, Dahdaleh M, Gebeily S, Inshasi J, Khalifa A, Pakdaman H, Szólics M, Yamout B. Biosimilars: opinion of an expert panel in the Middle East. Curr Med Res Opin 2008;24:2897-903.
32. Health Canada. Guidance for Sponsors: Information and submission requirements for subsequent entry biologics (SEBs). Available from.
33. Health Canada. Questions & Answers To Accompany the Final Guidance for Sponsors: Information and Submission Requirements for Subsequent Entry Biologics (SEBs). Available from.
34. Visiongain. Biosimilars and Follow-On Biologics: Global Market Outlook, 2010-2025. Available from.
35. IHS Global Insight. Japan's Ministry of Health, Labour and Welfare (MHLW) Issues Guidelines on Biosimilars Development and Regulatory Applications. Available from.
36. Sandoz Press Release 5 October 2009. Sandoz launches somatropin, the first-ever Japanese biosimilar, increasing access to key medicines in second largest global market. Available from.
37. European Medicines Agency. Assessment Report for epoetin zeta Retacrit. Nonproprietary Name: epoetin zeta (EMEA/H/C/872). Available from.
38. European Medicines Agency. Assessment Report for epoetin zeta Silapo. Nonproprietary Name: epoetin zeta (EMEA/H/C/760). Available from.
39. European Medicines Agency. Assessment Report for epoetin alfa Abseamed. Nonproprietary Name: epoetin alfa (EMEA/H/C/727). Available from.
40. European Medicines Agency. Assessment Report for epoetin alfa Binocrit. Nonproprietary Name: epoetin alfa (EMEA/H/C/725). Available from.
41. European Medicines Agency. Assessment Report for epoetin alfa Hexal. Nonproprietary Name: epoetin alfa (EMEA/H/C/726). Available from.
42. Schellekens H. Assessing the bioequivalence of biosimilars The Retacrit case. Drug Discov Today 2009;14:495-9.
43. European Medicines Agency. Assessment Report for Tevagrastim. Nonproprietary Name: filgrastim (EMEA/H/C/827). Available from.
44. European Medicines Agency. Assessment Report for Ratiograstim. Nonproprietary Name: filgrastim (EMEA/H/C/825). Available from.
45. European Medicines Agency. Assessment Report for Biograstim. Nonproprietary Name: filgrastim (EMEA/H/C/826). Available from.
46. European Medicines Agency. Assessment Report for Filgrastim ratiopharm. Nonproprietary Name: filgrastim (EMEA/H/C/824). Available from.
47. European Medicines Agency. CHMP Assessment Report for Zarzio. International Nonproprietary Name: filgrastim (EMEA/H/C/000917). Available from.
48. European Medicines Agency. CHMP Assessment Report for Filgrastim Hexal. International Nonproprietary Name: filgrastim (EMEA/H/C/918). Available from.
49. European Medicines Agency. Assessment Report for Nivestim. Nonproprietary Name: filgrastim (EMEA/H/C/001142). Available from.
50. Amgen Inc. Data on file, 2009.
51. ® Summary of Product Characteristics. Available from.
52. Aapro MS, Cameron DA, Pettengell R, et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 2006;42:2433-53.
53. Dale DC, Bonilla MA, Davis MW, et al. A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia. Blood 1993;81:2496-502.
54. Dale DC, Bolyard AA, Schwinzer BG, et al. The Severe Chronic Neutropenia International Registry: 10-Year Follow-up Report. Support Cancer Ther 2006;3:220-31.
55. Schellekens H. Biosimilar epoetins: how similar are they? Eur J Hosp Pharmacy 2004;3:43-7.
56. Sheridan B, Fox A. Feature on biopharmaceuticals: Views from the pharmaceutical industry - significant questions relating to efficacy and immunogenicity will remain at approval. Eur J Hosp Pharmacy Practice 2007;13:70-3.
57. European Group for Blood and Marrow Transplantation (EBMT). Position statement: biosimilar granulocyte-colony stimulating factor (G-CSF) for stem cell mobilization in related and unrelated donors. Available from.
58. Sitte HH. Biologicals, biosimilars, drug substitution: a mandatory sequence? Eur J Hosp Pharmacy Practice 2007;13:49-51.
59. Health Canada. Interchangeability/Substitutability of Subsequent Entry Biologics (SEBs) - Letter to Provincial/Territorial Drug Plan Directors July 29 2010.
60. European Medicines Agency. Summary of Product Characteristics - Retacrit 07/01/2009 Retacrit-H-C-872-II-16. Available from.
61. European Medicines Agency. Summary of Product Characteristics - Abseamed. 20/01/2010 Abseamed-H-C-727-II-18. Available from.
62. European Medicines Agency. Summary of Product Characteristics - Binocrit. 20/01/2010 Binocrit-H-C-725-II-18. Available from.
63. European Medicines Agency. Summary of Product Characteristics - Epoetin alfa Hexal. 20/01/2010 Epoetin alfa Hexal-H-C-726-II-18. Available from.
64. European Medicines Agency. Summary of Product Characteristics - Silapo.16/12/2009 Silapo-H-C-760-II-15. Available from.
65. European Medicines Agency. Summary of Product Characteristics - Ratiograstim. 06/10/2009 Ratiograstim-H-C-825-IA-05. Available from.
66. European Medicines Agency. Summary of Product Characteristics - Tevagrastim. Tevagrastim-H-C-827-II-04. Available from.
67. European Medicines Agency. Summary of Product Characteristics - Filgrastim Hexal. 21/10/2009 Filgrastim Hexal-H-C-918-II-02. Available from.
68. European Medicines Agency. Summary of Product Characteristics - Filgrastim ratiopharm. 15/09/2008 Filgrastim ratiopharm-H-C-824-00-00. Available from.
69. European Medicines Agency. Summary of Product Characteristics - Biograstim. 06/10/2009 Biograstim-H-C-826-IA-03. Available from.
70. European Medicines Agency. Summary of Product Characteristics - Zarzio. Zarzio-H-C-917-II-02. Available from.
71. European Medicines Agency. Summary of Product Characteristics - Nivestim. Nivestim EMEA/H/C/001142. Available from.
72. Kessler M, Goldsmith D, Schellekens H. Immunogenicity of biopharmaceuticals. Nephrol Dial Transplant 2006;21:v9-12.
73. Locatelli F, Roger S. Comparative testing and pharmacovigilance of biosimilars. Nephrol Dial Transplant 2006;21:v13-6.
74. Medicines and Healthcare products Regulatory Agency (MHRA). Drugs under intensive surveillance (Black Triangle List) - September 2010. Available from.
75. French Gazette. LOI no 2006-3062 du 3 mai 2006. Projet de loi portant diverses dispositions d'adaptation au droit communautaire dans le domaine du médicament. Available from.
76. German Bundesministerium der Justiz. German Social Law book, 'Aut idem'§ 129 section 4 sentence 1, January 17th 2008. Regulation Rahmenvertrag 20080117. Available from.
77. ND96/1973, article 13 (section 3) - Greek law on the sales of pharmaceutical products. 1973.
78. PD 340/1993 (article 23) Code of Ethics for Pharmacists in Greece. 1993.
79. Italian Council of State Opinion. Italian Council of State Opinion n.3992.07 based on a note by the Italian Ministry of Health, 2007.
80. FIRDPC Regulation on Interchangeability, September 2008. Available from.
81. Ministerio De Sanidad Y Consumo. 17420: ORDEN SCO/2874/2007, de 28 de septiembre, por la que se establecen los medicamentos que constituyen excepción a la posible sustitución por el farmacéutico con arreglo al articulo 86.4 de la Ley 29/2006, de 26 de Julio, de garantías y uso racional de los medicamentos y productos sanitarios. (Octubre 2007) Available from.
82. Swedish Medicines Agency (MPA) statement on substitution of biologics. Available from.
83. Proposal to the Department of Health's Ministerial Industry Strategy Group (MISG) on the substitution of biological medicines. Available from.
84. Czech Drug Law No 378/2007, § 83, article 2, valid as of January 1st, 2008. 2008 Jan 1.
85. Danish Medicines Agency. Approved Generic Substitution List. Available from.
86. Finnish Medicines Agency (FIMEA). Principles for compiling the list of mutually substitutable medicinal products with marketing authorisation at the Finnish Medicines Agency. 2009. Available from.
87. OGYI- Orzagos Gyogyszerezeti Intezet (Hungarian National Institute of Pharmacy). OGYI - Helyettesíthetõségi lista. A lista lezárásának idõpontja. Nov 2009. Available from.
88. NOMA. Norway's Medicines Agency (NOMA) - Biotilsvarende filgrastim tas midlertidig av Byttelisten. Available from.
89. NOMA. Norway's Medicines Agency (NOMA) Automatic Substitution List. 1 October 2010. Available from.
90. Slovakian Ministry of Health. Act of Slovakian Ministry of Health no. 209/2008, 2008.
91. Austrian Medical Law. ökonomische Verschreibung, RÖF 2005, 2005.
92. Krämer I, Jelkmann W Rekombinante Arzneimittel - medizinischer Fortschritt durch Biotechnologie. Hiedelberg: Springer Medizin Verlag, 2008.
93. Ledford H. The same but different. Nature 2007;449:274-6.